Cancer Biomarkers
A section of Cancers (ISSN 2072-6694).
Section Information
In the current era of precision medicine, cancer biomarkers provide critical data for predicting responses to therapies, generating prognoses of disease outcomes, and in determining oncogenic risk. Biomarkers are increasingly important as companions for drug discovery and development, and can help guide clinical decision-making. This section of Cancers aims to rapidly publish contributions on all aspects of Cancer Biomarkers. We encourage the submission of manuscripts that provide novel biomarkers, systematic reviews, and papers that report significant advances in cancer biomarkers. Topics include, but are not limited to:
- Genomic signatures
- RNA biomarkers
- miRNA biomarkers
- DNA biomarkers
- Protein biomarkers
- Metabolomic biomarkers
- Mutational biomarkers
- Circulating tumor cell (CTC) biomarkers
- Cellular biomarkers
- Imaging biomarkers
- Clinical biomarkers
- Biomarkers of drug response
- Biomarkers of genetic predisposition to cancer
- Biomarkers of cancer outcomes
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Liquid Biopsy for Lung Cancer Treatment (2nd Edition) (Deadline: 30 May 2026)
- Cancer Biomarkers—Detection and Evaluation of Response to Therapy (Deadline: 31 May 2026)
- The Role of Circulating Tumor Cells in Colorectal Cancer (Deadline: 31 May 2026)
- MicroRNA in Cancer: From Molecular Mechanisms to Therapeutic Applications (Deadline: 31 May 2026)
- Role of Cancer Biomarkers for Diagnosis, Prognosis and Targeted Therapy in Gastrointestinal Cancers (Deadline: 30 June 2026)
- Biomarkers for Cancer Immunotherapy (Deadline: 30 June 2026)
- Advances in Pancreatic Cancer: Exploring Biomarkers and Prognostic Predictors (Deadline: 30 June 2026)
- Molecular and Genetic Biomarkers in Oral Squamous Cell Carcinoma (Deadline: 30 June 2026)
- Novel Prognostic Biomarkers in Human Cancers: From Discovery to Application (Deadline: 5 July 2026)
- Molecular Signatures of Therapy: Biomarkers Predicting Response and Relapse in Cancer (Deadline: 15 July 2026)
- Recent Advances in Liquid Biopsy Biomarkers of Cancer (Deadline: 15 July 2026)
- Advances in Exosomes and Cancer Biomarkers (Deadline: 24 July 2026)
- Lung Cancer—Advances in Therapy and Prognostic Prediction (Deadline: 31 July 2026)
- Circulating Tumour DNA and Liquid Biopsy in Oncology (Deadline: 31 July 2026)
- Epigenetics and Non-Coding RNAs in Multiple Myeloma (Deadline: 15 August 2026)
- Genetic Changes in CNS Neoplasms (Deadline: 16 August 2026)
- Breast Cancer Biomarkers and Clinical Translation: 2nd Edition (Deadline: 20 August 2026)
- Diagnostic Biomarkers in Cancers Study (Deadline: 21 August 2026)
- Diagnosis and Biomarkers for Hematologic Malignancies (Deadline: 31 August 2026)
- Next-Generation Biomarkers in Oncology: From Multi-Omics to AI-Powered Diagnostics (Deadline: 31 August 2026)
- Liquid Biopsy Innovation: From ctDNA to RNA Modifications in Genitourinary Cancers (Deadline: 31 August 2026)
- Advancements in “Cancer Biomarkers” for 2025–2026 (Deadline: 31 August 2026)
- Decision-Making Biomarkers in the Treatment of Hepatocellular Carcinoma (Deadline: 30 September 2026)
- Biomarkers in the Management of Gynecological Cancer (Deadline: 30 September 2026)
- Biomarkers of Urological Cancers (Deadline: 30 September 2026)
- Biomarkers for Therapy Response in Gastrointestinal Malignancies: Predicting Outcomes and Personalizing Care (Deadline: 30 September 2026)
- Proteomic and Oncogenic Biomarkers in Gastrointestinal Cancer (Deadline: 30 September 2026)
- Emerging Biomarkers for Precision Oncology in Gastrointestinal Cancers (Deadline: 1 October 2026)
- Advancing Precision Oncology: From Biomarker Discovery to Clinical Validation (Deadline: 20 October 2026)
- Solid Tumors, with a Focus on Urological Cancers: From Molecular Mechanisms to Predictive Biomarkers (Deadline: 30 October 2026)
- The Biomarkers of Oral Cancer (Deadline: 31 October 2026)
- Prognostic Markers in Endometrial Cancer (Deadline: 31 October 2026)
- Genetic, Epigenetic and Protein Biomarkers in Gynaecological and Breast Cancers (Deadline: 31 October 2026)
- Epigenetic Modifications as Biomarkers of Tumor Development (Deadline: 31 October 2026)
- Biomarkers in the Management of Lung Cancer (Deadline: 31 October 2026)
- Metabolomic Biomarkers for Cancers (Deadline: 31 October 2026)
- Clinical and Molecular Biomarkers in Breast Cancer Management (Deadline: 5 November 2026)
- Tumor Microenvironment Biomarkers: Bridging Immunology and Metastasis (Deadline: 30 November 2026)
- Tumor Biomarkers in Precision Oncology: From Non-Coding RNAs to Functional Protein (Deadline: 1 December 2026)
- Immune Biomarkers in Solid Tumors: From Peripheral Blood Parameters to Tissue-Based Indicators for Prognosis and Therapy Response (Deadline: 31 December 2026)
- Emerging Biomarkers for Immune Checkpoint Inhibitor Sensitivity and Resistance in Non-Small-Cell Lung Cancer (Deadline: 20 April 2027)
Topical Collections
Following topical collections within this section are currently open for submissions:
